Novartis has spent considerable time and energy building its presence in the IgA nephropathy (IgAN) disease area, and now | ...

Moderna, Inc. remains under pressure in 2025, despite recent next-gen COVID vaccine approval & cancer vaccine trial. Learn ...

Perth-based biotech Argenica Therapeutics, which is developing treatments to reduce brain tissue death after stroke, plans to ...

Auxora has been assessed in efficacy trials including the Phase IIb CARPO trial for SIRS and acute pancreatitis.

UEFA Technical Observer Joe Montemurro highlights Manchester United's defensive mettle in their Matchday 2 victory over ...

With world leaders set to gather in Brazil for COP30 in November, new analysis from an international team of climate policy ...

Ozak AI’s presale is already booming in the crypto industry. Many investors and whales have started transferring their money ...

IFSC Grade A Exam Analysis 2025 with Phase 1 concluded with moderate difficulty. Paper 1 doable, Paper 2 moderate to tough.

NMPA’s response is based on the Phase 3 DRAGON interim analysis resultsTopline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a ...

Advances in mass spectrometry and chromatography are enhancing pesticide residue analysis, focusing on exposomics and risk assessment for improved food safety. Ion chromatography is evolving with new ...

The Gaza ceasefire agreement was mediated by the United States along with Egypt, Qatar and Turkey. Its second phase calls for ...

Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.